Effects of Whole-Body Gamma Irradiation and 5-Androstenediol Administration on Serum G-CSF

References

• Singh V.K., Seed T.M. Radiation effects. Physician’s Guide to Terrorist Attack, J.M. Roy. Humana Press, Totowa, NJ 2003; 339–362
   Google Scholar
• Pellmar T.C., Rockwell S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat. Res. 2005; 163: 115–123, [CSA]
   PubMedGoogle Scholar
• Culy C.R., Spencer C.M. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001; 61: 641–684, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• MacVittie T.J., Farese A.M. Cytokine-based treatment for acute radiation-induced myelosuppression: preclinical and clinical perspective. The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims, R.C. Ricks, M.E. Berger, F.M. O’Hara. Parthenon, Boca Raton, FL 2002; 53–72
   Google Scholar
• Van der Meeren A., Mouthon M.A., Vandamme M., Squiban C., Aigueperse J. Combinations of cytokines promote survival of mice and limit acute radiation damage in concert with amelioration of vascular damage. Radiat. Res. 2004; 161: 549–559, [CSA]
   PubMed Web of Science ®Google Scholar
• MacVittie T.J., Farese A.M. Experimental approaches to treatment of radiation-induced hematopoietic injury. Radiation Toxicology: Bone Marrow and Leukemia, J.H. Henry, B.I. Lord. Taylor and Francis, London 1995; 141–194
   Google Scholar
• Horner A.A., Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J. Allergy Clin. Immunol. 2002; 110: 706–712, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hauer-Jensen M., Fink L.M., Wang J. Radiation injury and the protein C pathway. Crit. Care Med. 2004; 32: S325–330, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Davison B., Large D.M., Anderson D.C., Robertson W.R. Basal steroid production by the zona reticularis of the guinea-pig adrenal cortex. J. Steroid Biochem. 1983; 18: 285–290, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Whitnall M.H., Driscoll W.J., Lee Y.C., Strott C.A. Estrogen and hydroxysteroid sulfotransferases in guinea pig adrenal cortex: cellular and subcellular distributions. Endocrinology 1993; 133: 2284–2291, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Regelson W., Loria R., Kalimi M. Dehydroepiandrosterone (DHEA)—the “mother steroid”. I. Immunologic Action Ann. NY Acad. Sci. 1994; 719: 553–563, [CSA]
   PubMed Web of Science ®Google Scholar
• Bird C.E., Morrow L., Fukumoto Y., Marcellus S., Clark A.F. Delta5-androstenediol: kinetics of metabolism and binding to plasma proteins in normal men and women. J. Clin. Endocrinol. Metab. 1976; 43: 1317–1322, [CSA]
   PubMed Web of Science ®Google Scholar
• Seki M., Kimura T., Takayama T., Yanaihara T., Nakayama T. [Biosynthesis of steroids by human fetal kidney perfused in vitro (author’s transl)]. Acta Obstet. Gynaecol. Jpn. 1981; 33: 805–812, [CSA]
   PubMedGoogle Scholar
• Hernandez-Pando R., De La Luz Streber M., Orozco H., Arriaga K., Pavon L., Al-Nakhli S.A., Rook G.A. The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice. Immunology 1998; 95: 234–241, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Araghi-Niknam M., Liang B., Zhang Z., Ardestani S.K., Watson R.R. Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS). Immunology 1997; 90: 344–349, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Whitnall M.H., Elliott T.B., Harding R.A., Inal C.E., Landauer M.R., Wilhelmsen C.L., McKinney L., Miner V.L., Jackson W.E., 3rd, Loria R.M., Ledney G.D., Seed T.M. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice. Int. J. Immunopharmacol. 2000; 22: 1–14, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Loria R.M. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids 2002; 67: 953–966, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Whitnall M.H., Inal C.E., Jackson W.E., 3rd, Miner V.L., Villa V., Seed T.M. In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. Radiat. Res. 2001; 156: 283–293, [CSA]
   PubMed Web of Science ®Google Scholar
• Whitnall M.H., Villa V., Benjack J., Miner V.L., Seed T.M., Jackson W.E., 3rd. Effects of the novel systemic radioprotectant 5-androstenediol on phagocytosis and oxidative burst in monocytes and granulocytes from mice exposed to whole-body gamma irradiation. Proceedings. 49th Annual Radiation Research Meeting. 2002
   Google Scholar
• Stickney D.R., Dowding C., Garsd A., Whitnall M.H., Frincke J. HE2100 and HE3204 protect rhesus macaques from radiation-induced myelosuppression. Proceedings. Annual Meeting of the European Society for Radiation Biology, Budapest, 2004
   Google Scholar
• Singh V.K., Yadav V.S. Role of cytokines and growth factors in radioprotection. Exp. Mol. Pathol. 2005; 78: 156–169, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Neta R. Modulation with cytokines of radiation injury: suggested mechanisms of action. Environ. Health Perspect. 1997; 105(Suppl 6)1463–1465, [CSA]
   PubMed Web of Science ®Google Scholar
• Neta R. Modulation of radiation damage by cytokines. Stem Cells 1997; 15(Suppl 2)87–94, [CSA]
   PubMed Web of Science ®Google Scholar
• MacVittie T.J., Farese A.M. Cytokine-based treatment of radiation injury: potential benefits after low-level radiation exposure. Mil. Med. 2002; 167: 68–70, [CSA]
   PubMedGoogle Scholar
• Mehrotra S., Mishra K.P., Maurya R., Srimal R.C., Yadav V.S., Pandey R., Singh V.K. Anticellular and immunosuppressive properties of ethanolic extract of Acorus calamus rhizome. Int. Immunopharmacol. 2003; 3: 53–61, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Arroyo C.M., Burman D.L., Kahler D.W., Nelson M.R., Corun C.M., Guzman J.J., Smith M.A., Purcell E.D., Hackley B.E., Jr., Soni S.D., Broomfield C.A. TNF-alpha expression patterns as potential molecular biomarker for human skin cells exposed to vesicant chemical warfare agents: sulfur mustard (HD) and Lewisite (L). Cell Biol. Toxicol. 2004; 20: 345–359, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Xu Y., Kulkosky J., Acheampong E., Nunnari G., Sullivan J., Pomerantz R.J. HIV-1-mediated apoptosis of neuronal cells: proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc. Natl. Acad. Sci. USA. 2004; 101: 7070–7075, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dale D.C. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62(Suppl 1)1–15, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Boclek R.C., Armitage J.O. Hematopoietic growth factors. Cancer J. Clin. 1996; 46: 165–184, [CSA]
   PubMed Web of Science ®Google Scholar
• Gerber A., Struy H., Weiss G., Lippert H., Ansorge S., Schulz H.U. Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients. J. Interferon Cytokine Res. 2000; 20: 1083–1090, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ishikawa K., Tanaka H., Matsuoka T., Shimazu T., Yoshioka T., Sugimoto H. Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia. J. Trauma. 1998; 44: 1047–1054, discussion 1054–1045[CSA]
   PubMed Web of Science ®Google Scholar
• Wenisch C., Werkgartner T., Sailer H., Patruta S., Krause R., Daxboeck F., Parschalk B. Effect of preoperative prophylaxis with filgrastim in cancer neck dissection. Eur. J. Clin. Invest. 2000; 30: 460–466, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chuang P.I., Yee E., Karsan A., Winn R.K., Harlan J.M. A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem. Biophys. Res. Commun. 1998; 249: 361–365, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lieschke G.J., Grail D., Hodgson G., Metcalf D., Stanley E., Cheers C., Fowler K.J., Basu S., Zhan Y.F., Dunn A.R. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737–1746, [CSA]
   PubMed Web of Science ®Google Scholar
• Ikebuchi K., Clark S.C., Ihle J.N., Souza L.M., Ogawa M. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 1988; 85: 3445–3449, [CSA]
   PubMed Web of Science ®Google Scholar
• Peterson V.M., Adamovicz J.J., Elliott T.B., Moore M.M., Madonna G.S., Jackson W.E., 3rd, Ledney G.D., Gause W.C. Gene expression of hematoregulatory cytokines is elevated endogenously after sublethal gamma irradiation and is differentially enhanced by therapeutic administration of biologic response modifiers. J. Immunol. 1994; 153: 2321–2330, [CSA]
   PubMed Web of Science ®Google Scholar
• Chang C.M., Limanni A., Baker W.H., Dobson M.E., Kalinich J.F., Jackson W., Patchen M.L. Bone marrow and splenic granulocyte-macrophage colony-stimulating factor and transforming growth factor-beta mRNA levels in irradiated mice. Blood 1995; 86: 2130–2136, [CSA]
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Souza L., Waddick K.G., Wick M., Song C.W. In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. Blood 1990; 75: 638–645, [CSA]
   PubMed Web of Science ®Google Scholar
• Waddick K.G., Song C.W., Souza L., Uckun F.M. Comparative analysis of the in vivo radioprotective effects of recombinant granulocyte colony-stimulating factor (G-CSF), recombinant granulocyte-macrophage CSF, and their combination. Blood 1991; 77: 2364–2371, [CSA]
   PubMed Web of Science ®Google Scholar
• Waselenko J.K., MacVittie T.J., Blakely W.F., Pesik N., Wiley A.L., Dickerson W.E., Tsu H., Confer D.L., Coleman C.N., Seed T., Lowry P., Armitage J.O., Dainiak N. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann. Intern. Med. 2004; 140: 1037–1051, [CSA]
   PubMed Web of Science ®Google Scholar
• MacVittie T.J., Monroy R.L., Patchen M.L., Souza L.M. Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. Int. J. Radiat. Biol. 1990; 57: 723–736, [CSA]
   PubMed Web of Science ®Google Scholar
• Schuening F.G., Storb R., Goehle S., Graham T.C., Appelbaum F.R., Hackman R., Souza L.M. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1989; 74: 1308–1313, [CSA]
   PubMed Web of Science ®Google Scholar
• Drouet M., Mourcin F., Grenier N., Leroux V., Denis J., Mayol J.F., Thullier P., Lataillade J.J., Herodin F. Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis. Blood 2004; 103: 878–885, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar